Trials / Conditions / Stage IIIA Ovarian Cancer

Stage IIIA Ovarian Cancer

23 registered clinical trials studyying Stage IIIA Ovarian Cancer — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Withdrawn	PET Imaging of Ovarian Carcinoma With 18F-FSPG NCT02872519	Vanderbilt-Ingram Cancer Center	EARLY_Phase 1
Withdrawn	Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Perito NCT02833506	Roswell Park Cancer Institute	Phase 1
Completed	Intravital Microscopy in Evaluating Patients With Primary Peritoneal, Fallopian Tube, or Stage IA-IV Ovarian C NCT03297489	Roswell Park Cancer Institute	EARLY_Phase 1
Completed	Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer NCT03154190	Stanford University	N/A
Terminated	IGFBP-2 Vaccine and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, o NCT03029611	University of Washington	Phase 2
Withdrawn	Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery an NCT02567396	National Cancer Institute (NCI)	Phase 1
Completed	Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations NCT02646319	Mayo Clinic	EARLY_Phase 1
Completed	Carevive Survivor Care Planning System in Improving Quality of Life in Breast Cancer Survivors NCT03198286	Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University	N/A
Withdrawn	Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian NCT02470559	Barbara Ann Karmanos Cancer Institute	Phase 1
Completed	Taking Care of Her Program in Patients With Stage III or IV Ovarian Cancer and Spouse Caregivers NCT02401321	University of Washington	N/A
Completed	Vaccine Therapy and Cyclophosphamide in Treating Patients With Stage II-III Breast or Stage II-IV Ovarian, Pri NCT01606241	Mayo Clinic	Phase 1
Completed	Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors NCT01522820	Roswell Park Cancer Institute	Phase 1
Terminated	Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherap NCT01275664	Gynecologic Oncology Group	N/A
Completed	OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Ca NCT00857545	Gynecologic Oncology Group	Phase 2
Completed	Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors NCT01131234	National Cancer Institute (NCI)	Phase 1
Completed	Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritone NCT01080521	Gynecologic Oncology Group	—
Completed	Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian NCT02311907	Alliance for Clinical Trials in Oncology	Phase 3
Completed	Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Isl NCT01010126	National Cancer Institute (NCI)	Phase 2
Terminated	YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal NCT00899093	Gynecologic Oncology Group	—
Completed	Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian NCT00262847	National Cancer Institute (NCI)	Phase 3
Recruiting	Study of Tumor Tissue Samples From Patients Who Have Undergone Surgery for Advanced Stage III or Stage IV Ovar NCT01000259	Gynecologic Oncology Group	—
Withdrawn	Research Study in Patients With Advanced Ovarian Epithelial Cancer NCT00053235	Gynecologic Oncology Group	—
Completed	Collecting Tumor Samples From Patients With Gynecological Tumors NCT00897442	Gynecologic Oncology Group	—